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Background/aim: This study aims to investigate the association between polycystic ovary syndrome (PCOS) and obesity and insulin
resistance (IR) with respect to anti-Müllerian hormone (AMH), inhibin A (INH-A), inhibin B (INH-B), and insulin-like peptide 3
(INSL3) levels, all factors which may have an impact on IR.
Materials and methods: In this cross sectional study, 52 adolescent girls diagnosed with PCOS [groups: nonobese (NO), n = 23;
overweight/obese (OW/O), n = 29] were included. Blood samples were obtained to measure AMH, INH-B, INH-A, and INSL3 levels,
together with hormonal and biochemical assessments. Oral glucose tolerance test (OGTT) was performed and the indexes of IR
[homeostasis model assessment: insulin resistance (HOMA-IR) and Matsuda index] were calculated.
Results: Insulin resistance was 56.5% with OGTT and 30.4% with HOMA-IR in nonobese-PCOS girls. There was a correlation between
INH-A and HOMA-IR even when controlled for body mass index (BMI). INH-B and FAI also had correlations with HOMA-IR which
disappeared when controlled for BMI. In regression analyses, AMH (odds ratio = [0.903, P = 0.015) and FAI (odds ratio = 1.353, P
= 0.023) are found to be contributors to IR. Their effect was BMI-independent. In ROC analysis, the cutoff value for FAI was 5.93
(sensitivity 71%) to define IR in PCOS girls.
Conclusion: AMH and FAI may contribute to IR (defined by OGTT) in PCOS. FAI might be used as a supporting IR marker (defined
by OGTT) in adolescent girls with PCOS.
Key words: Adolescent, anti-Müllerian hormone, free androgen index, inhibin A, inhibin B, insulin resistance, polycystic ovary
syndrome

1. Introduction
The frequency of obesity and insulin resistance (IR) is
gradually increasing and has a significant association with
reproductive endocrinology and menstrual dysregulation,
especially in adolescents [1,2]. Obesity and/or IR may
lead to an increase in the incidence of polycystic ovary
syndrome (PCOS) in adolescents, but may also cause
hirsutism and menstrual irregularities even in the absence
of PCOS [3,4].
Studies related to new hormones, cytokines, and
proteins that help to predict a diagnosis of PCOS and clarify
the etiopathogenesis are ongoing [5–10]. A recent study
[10] reported that, in addition to anti-Müllerian hormone

(AMH), inhibin A (INH-A) could be used as a marker for
PCOS. The relationship between these biomarkers and
glucose/insulin metabolism in patients with PCOS has
been investigated in some studies [8,9,11]. It is known that
AMH levels are positively correlated with the number of
preantral and small antral follicles [12], and high insulin
levels have been found to be associated with antral follicle
count and ovarian volume [13]. Recently, a study involving
only adolescents and young adults found that the AMH
level was elevated in adolescent girls with PCOS who were
nonobese and had IR [14]. The relationship between AMH
and obesity/IR has been investigated in some studies, but
most of them have been conducted with adults and/or have
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evaluated IR using the homeostasis model assessment:
insulin resistance (HOMA-IR) index [11,14–17]. Only a
small number of studies have examined glucose/insulin
metabolism by way of the clamp test and/or oral glucose
tolerance test (OGTT) [17–19].
It has been reported that hyperinsulinemia stimulates
steroid hormone synthesis in the ovaries, increases the
production of androgens, and inhibits the synthesis
of steroid hormone binding globulin (SHBG) and
IGFBP-1, which binds IGF-1 in the liver [20,21]. Inhibin
B (INH-B) and INH-A, released from granulosa cells
in the ovaries and involved in follicle development, are
also possibly related to IR and/or obesity. It has been
suggested that INH-B levels are inversely correlated with
body mass index (BMI) in patients with PCOS and that
INH-B levels are suppressed by insulin [22,23]. There is
limited data about the relation between INH-A levels
and insulin secretion [9], and there is no research data
from adolescent age groups on this issue. Investigations
into the relationship between these biomarkers and IR
could illuminate the pathophysiology of PCOS.
A new protein being studied as a possible diagnostic
biomarker in patients with PCOS is insulin-like
peptide-3 (INSL3), which is released from theca cells
of the follicles, the corpus luteum, and ovarian stroma
and the levels of which increase at the onset of puberty,
like insulin, IGF-1, and IGF-BP3. It has been found to
be related to luteinizing hormone (LH)-dependent
hyperandrogenism, especially in patients with PCOS
who have normal body weights [7]. However, INSL3 was
not investigated in adolescent girls with PCOS in terms
of IR and/or obesity.
In this study, we aimed to investigate the relationship
of obesity/IR with hyperandrogenemia and the levels
of specific biomarkers (AMH, INSL3, INH-B, and
INH-A) that may have an impact on IR and contribute
to emergence of disease in adolescent girls with PCOS.
We also aimed to determine the usage areas of these
biomarkers in PCOS and contribute to the clarification
of its pathophysiology.
2. Materials and methods
2.1. Study design and subjects
Fifty-two adolescent girls aged 14.5 to 20 years who
were consecutively admitted to a pediatric endocrine
outpatient clinic between August 2014 and August
2015 were recruited for this cross sectional study. All of
the girls had been diagnosed with PCOS based on the
Rotterdam criteria. The exclusion criteria are described
elsewhere [10]. Written consent was obtained from all
participants and their parents. Ethical approval was
obtained from the local ethics committee (no. 2421).
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2.2. Methods
2.2.1. Clinical evaluation
Anthropometric measurements (height, weight, and waist
and hip circumference) and scoring of body hair growth
using the Ferriman–Gallwey scale [24] were taken for
all participants by an experienced physician as described
elsewhere [10]. Standard deviation scores (SDS) were
calculated according to national data [25–27]. BMI was
calculated using the formula BMI = weight (kg)/height
(m2). The study group was divided into 2 groups based on
BMI: a) the nonobese group (PCOS-NO), who had normal
weights (BMI SDS < 1), and b) the overweight (OW) and
obese group (PCOS-OW/O), who had been classified as
overweight (1–2 BMI SDS) or obese (BMI SDS > 2). Blood
pressures (BP) were measured by the same physician, and
the SDSs of these measurements were calculated using
data from the National High Blood Pressure Education
Program Working Group [28].
2.2.2. Laboratory evaluation and biochemical assays
Blood samples for laboratory analysis of glucose,
insulin, FSH, LH, SHBG, dehydroepiandrosteronesulfate (DHEAS), total testosterone (T), androstenedione
(D4-A), AMH, INSL3, INH-B, and INH-A were drawn
between 8:00 AM and 8:30 AM after an overnight fast.
Basal 17-hydroxyprogesterone (17-OHP), free thyroxine,
thyroid-stimulating hormone (TSH), cortisol, and prolactin
levels were measured to exclude adrenal enzyme defects,
thyroid hormone defects, and intracranial pathologies.
The blood samples were immediately centrifuged, and the
serum samples were stored at −80 °C until assaying. Free
androgen index (FAI) was calculated using T and SHBG
values in the equation FAI = 100 × (T/SHBG).
The HOMA-IR index was calculated as (insulin [µU/
mL] × glucose [mg/dL]) / 405 [29]. HOMA-IR > 2.5
was used to define IR [29]. A standard 75 g OGTT was
performed after an overnight fast of at least 8 h but not
exceeding 14 h. Venous blood was sampled at 0, 30, 60,
90, and 120 min after glucose intake, and all the venous
plasma samples were centrifuged and analyzed for glucose
and insulin immediately after blood collection. The whole
body insulin sensitivity index (ISIcomp, Matsuda index) was
calculated as 10000 / (√ (fasting glucose x fasting insulin)
× (mean glucose x mean insulin on OGTT) [30]. Glucose
abnormalities were assessed according to American
Diabetes Association criteria [31]. Fasting levels of insulin
greater than 15 µU/mL, or insulin peak (post-OGTT)
levels of more than 150 µU/mL and/or more than 75 µU/
mL at 120 minutes of OGTT are hyperinsulinemic levels,
which infer IR in adults [32]. The study group was divided
into 2 subgroups according to sum of insulin levels during
OGTT as follows: a) IR ≥ 300 µU/mL and b) without IR <
300 µU/mL [33].
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2.2.3. Assays
Plasma glucose was measured using the hexokinase method
with standard equipment and methods (Roche Diagnostics
with Cobas Integra kits, Basel, Switzerland). Insulin (IU/
mL) was measured using the immunoradiometric assay
method (IRMA) (DIA source ImmunoAssays, S.A.,
Nivelles, Belgium), and the lowest value of detection was
1 IU/mL. Intra- and interassay coefficients of the variation
(CVs) were 1.5%–2.1% and 6.1%–6.5%, respectively. Leptin
was measured using ELISA with intra- and interassay CVs
of < 10% and < 6%, respectively (Abcam Inc, Cambridge,
MA, USA). The levels of the other plasma hormones (LH,
FSH, SHBG, DHEAS, T, D4-A, AMH, INH-A, INH-B,
INSL3, 17-OHP, cortisol, FT4, and TSH) were measured
using assays described elsewhere [10].
2.3. Statistical analysis
SPSS 15 (IBM, Chicago, IL, USA) was used for statistical
analysis. Mean ± SD or median (minimum–maximum)
were given for the results. Three different methods
(variability coefficient, skewness-kurtosis, and the
Kolmogorov–Smirnov values) were used for normality
tests of continuous variables, and findings in two of
these three methods were considered to confirm normal
distribution.
Intergroup comparisons were analyzed using
parametric and nonparametric tests. For comparison of
categorical variables, the chi-square test was used, and
for comparison of continuous variables, Student’s t-test
was used. For irregularly distributed parameters, we
applied the Mann–Whitney U test, and the Spearman and
Pearson correlation parameters were used for correlation
analyses. A logistic regression model was applied using a
backward step-wise method with the dependent variable
of the presence of IR (defined by OGTT) and independent

variables of FAI, AMH, INH-A, INH-B, INSL3, leptin, and
BMI SDS.
3. Results
3.1. Clinical findings
There was a higher frequency of acanthosis nigricans and
hirsutism in the PCOS-OW/O group than in the PCOS-NO
group (P < 0.001 and P = 0.024, respectively). Additionally,
as expected, weight SDS, BMI SDS, waist circumference
(WC) SDS, and waist/hip ratio (WHR) were higher in the
PCOS-OW/O group than in the PCOS-NO group. The
systolic BP SDS and diastolic BP SDS values were similar
in both groups (data not shown). A comparison of the
clinical findings is shown in Table 1.
3.2. Glucose and lipid metabolism
The HOMA-IR index level was higher and the Matsuda
index value was lower in the PCOS-OW/O group
than in the PCOS-NO group (P = 0.001 and P = 0.002,
respectively). The rate of IR detected by HOMA-IR in the
PCOS-NO group was significantly lower than the rate
detected by OGTT (30.4% and 56.5%, respectively), but
there were no significant differences in the PCOS-OW/O
group (72.4% and 79.3%, respectively). The detection of
glucose intolerance was similar in the PCOS-NO and
PCOS-OW/O groups (8.7% and 6.9%, respectively) (Table
2), and no patient fulfilled the criteria for metabolic
syndrome. In terms of lipid metabolism, all parameters
were similar between the two groups (data not shown).
3.3. Hormone profile
SHBG level was statistically significantly lower, and the
D4-A and FAI were higher, in the PCOS-OW/O group
than in the PCOS-NO group. There were no differences
shown in INH-A between the PCOS-OW/O group and

Table 1. Some clinical findings of the patients with PCOS.
Patients with PCOS
(nonobese) n = 23

Patients with PCOS
(obese) n = 29

P-value

Age (years)

16.84 ± 1.36

16.64 ± 1.48

0.608

Menarcheal age (yrs)

12.59 ± 1.50

12.50 ± 1.27

0.822

BW SDS

−0.38 [−2.30 to 3.79]

0.19 [−3.66 to 3.11]

0.793

Height SDS

−0.48 [−3.30 to 1.58]

0.00 [−2.33 to 2.89]

0.056

Weight SDS

−0.56 [−2.88 to 1.11]

2.33 [0.91 to 5.41]

<0.001

BMI SDS

−0.60 [−1.74 to 0.98]

2.39 [1.28 to 9.20]

<0.001

WC SDS

1.01 [0.06 to 3.63]

4.98 [2.93 to 10.47]

<0.001

WHR

0.83 ± 0.05

0.89 ± 0.05

<0.001

PCOS: Polycyctic ovary syndrome, SDS: Standard deviation score, BW: Birth weight, SGA: Small for
gestational age, AGA: Appropriate for gestational age, LGA: Large for gestational age, BMI: Body
Mass Index, WC: Waist circumference, WHR: Waist-hip ratio
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the. PCOS-NO group. INSL3 and INH-B levels were
statistically significantly lower in the PCOS-OW/O group
than in the PCOS-NO group. A comparison of hormone
levels between the groups is presented in Table 3.
3.4. Correlation analysis
Luteinizing hormone, FSH, total T, DHEAS, AMH, and
INH-A showed no correlations with anthropometric

measurements. BMI SDS was significantly correlated with
FAI, D4-A, leptin, SHBG, and INH-B (r = 0.519, P < 0.001;
r = 0.372, P = 0.011; r = 0.612, P < 0.001; r = −0.525, P
< 0.001; and r = −0.368, P = 0.007, respectively), and WC
SDS showed similar correlations.
Inhibin B was significantly correlated with both
the HOMA-IR index and the Matsuda index without

Table 2. Laboratory findings of the patients with PCOS regarding glucose metabolism.
Patients with PCOS
(nonobese) n = 23

Patients with PCOS
(obese) n = 29

P-value

Fasting glucose (mg/dL)

69.87 ± 6.38

71.45 ± 8.94

0.478

Fasting insulin (µU/mL)

11.64 ± 6.23

24.48 ± 16.83

0.001

2-h glucose (mg/dL)

108.86 ±27.47

102.93 ± 27.61

0.314

Glucose intolerance (2-h glucose) n(%)

2 (8.7)

2 (6.9)

0.806

Mean serum insulin (µU/mL)

86.75 ± 64.79

110.05 ± 60.02

0.196

Matsuda index

4.98 ± 2.43

3.06 ± 1.74

0.002

HOMA-IR

2.04 ± 1.16

4.35 ± 3.00

0.001

Presence of IR (with HOMA-IR) n(%)

7 (30.4)

21 (72.4)

0.004

Presence of IR (with OGTT) n(%)

13 (56.5)

23 (79.3)

0.071

PCOS: Polycyctic ovary syndrome, IR: Insulin resistance, HOMA-IR: Homeostasis model assessment-insulin resistance,
OGTT: Oral glucose tolarence test, SDS: Standard deviation score.
Table 3. Some laboratory findings of the patients with PCOS.
Patients with PCOS
(nonobese) n = 23

Patients with PCOS
(obese) n = 29

P-value

LH (mU/mL)

10.60 [4.70–79.10]

10.60 [3.00–25.80]

0.755

FSH (mU/mL)

5.00 ± 1.83

5.41 ± 1.69

0.419

LH/FSH ratio

3.23 ± 2.58

2.19 ± 0.89

0.077

D4-A (ng/mL)

4.03 ± 1.43

5.75 ± 2.32

0.004

DHEA-S (µg/dL)

284.60 ± 118.14

314.13 ±127.75

0.396

T (ng/mL)

0.44 [0.19– 1.03]

0.47 [0.16–2.21]

0.536

SHBG (ng/mL)

13.23 ± 8.64

7.19 ±4.81

0.008

FAI [100 × (T/SHBG)]

3.35 [0.97–13.04]

8.67 [2.30–23.65]

0.002

Leptin (ng/mL)

6.24 ± 2.98

11.23 ± 5.81

<0.001

AMH (ng/mL)

12.36 ± 9.06

18.07 ± 13.14

0.071

INH-A (pg/mL)

28.50 [1.76–239.70]

30.54 [1.68–307.10]

0.692

INH-B (pg/mL)

92.28 ± 63.44

54.74 ± 30.97

0.014

INSL3 (pg/mL)

1353.69 ± 289.19

1179.69 ± 264.58

0.028

Data is expressed as either number, mean ± SD or median (min-max) for variables showed abnormal
distribution.
PCOS: Polycyctic ovary syndrome, LH: Luteinizing hormone, FSH: Follicle-stimulating hormone,
T: Testosterone, SHBG: Sex hormone binding globulin, FAI: Free androgen index, DHEAS:
dehydroepiandrosterone-sulphate, DA-4: Androstenedione, AMH: Anti-Müllerian hormone, INH-A:
Inhibin A, INH-B: Inhibin B, INSL3: Insulin-like peptide-3.
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3.5. Regression analysis
In logistic regression analysis performed with the
dependent variable of IR presence (defined using OGTT)
and the independent variables of FAI, AMH, INH-A,
INH-B, INSL3, leptin, and BMI SDS; the variables of
INH-A, INH-B, INSL3, and also BMI SDS were excluded
through the steps. The significant contributors of IR were
FAI [odds ratio (95% Cl) = 1.353 (1.042–1.756), P = 0.023],
and AMH [odds ratio (95% Cl) = 0.903 (0.832–0.981), P =
0.015].
3.6. Receiving operating curve (ROC) analysis
FAI was found to be an IR marker (defined using OGTT)
at the cutoff value of 5.93 with 71% sensitivity and 67%
specificity (area under curve: 69.9%; P = 0.03; 95% CI=
0.546–0.852) (Figure). In ROC analysis performed for
AMH to be an IR marker, sensitivity and specificity

controlling for BMI SDS. However, in partial correlation
analysis performed by removing the BMI effect, INH-B
was only correlated with the Matsuda index (r = 0.291,
P = 0.044). Inhibin A was significantly correlated with
HOMA-IR even after controlling for the BMI effect
(r = −0.324, P = 0.025). Anti-Müllerian hormone had no
correlation with HOMA-IR or the Matsuda index with or
without BMI effect. SHBG had a negative correlation with
HOMA-IR, but no correlation was found after controlling
for BMI. And no correlation was found between SHBG
and the Matsuda index. FAI was significantly correlated
with both HOMA-IR and the Matsuda index, but in
partial correlation analysis performed by removing BMI
effect, these correlations disappeared. The correlations of
hormone levels, and FAI with HOMA-IR and the Matsuda
index (with and without BMI effect) are shown in Table 4.

Table 4. Correlations of hormone levels and FAI with HOMA-IR and Matsuda index (with and
without BMI effect) in the patients with PCOS.
With BMI effect
(not controlled for BMI)

HOMA-IR

Matsuda index

r

P

r

P

D4-A (ng/mL)

0.416

0.004

−0.246

0.111

T (ng/mL)*

0.068

0.635

−0.241

0.099

SHBG (ng/mL)

−0.323

0.027

0.296

0.051

FAI*

0.358

0.014

−0.531

<0.001

Leptin (ng/mL)

0.496

<0.001

−0.439

0.002

AMH (ng/mL)

−0.066

0.641

0.182

0.212

INH-A (pg/mL)*

−0.284

0.042

0.272

0.059

INH-B (pg/mL)

−0.386

0.005

0.429

0.002

INSL3 (pg/mL)

0.187

0.186

−0.103

0.480

Without BMI effect
(controlled for BMI)

HOMA-IR
r

P

r

P

D4-A (ng/mL)

0.217

0.167

-0.073

0.648

T (ng/mL)*

0.031

0.838

−0.126

0.397

SHBG (ng/mL)

0.013

0.934

0.043

0.783

FAI*

0.253

0.106

−0.246

0.117

Leptin (ng/mL)

−0.038

0.797

−0.159

0.282

AMH (ng/mL)

−0.119

0.421

0.220

0.133

INH-A (pg/mL)*

−0.324

0.025

0.247

0.091

INH-B (pg/mL)

−0.147

0.318

0.291

0.044

INSL3 (pg/mL)

0.301

0.038

−0.134

0.365

Matsuda index

*Spearman correlation analysis was used for these irregularly scattered parameters.
PCOS: Polycyctic ovary syndrome, HOMA-IR: Homeostasis model assessment-insulin
resistance, SDS: Standard deviation score, T: Testosterone, SHBG: Sex hormone binding
globulin, FAI: Free androgen index, DA-4: Androstenedione, AMH: Anti-Müllerian hormone,
INH-A: Inhibin A, INH-B: Inhibin B, INSL3: Insulin-like peptide-3.
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Figure. ROC analysis for FAI to define the cutoff values that can
be used as an insulin resistance sign.

were low (at the cutoff value of 10, 50% sensitivity, 69%
specificity, area under curve: 32.6%; P = 0.047; 95% CI =
0.171–0.482).
4. Discussion
The role of specific biomarkers (AMH, INH-A, INH-B,
INSL3) and hyperandrogenemia in pathophysiology of
PCOS and the association of them with obesity and/or
IR have been investigated in different studies; however,
to the best of our knowledge, this study is the only one
that analyzed the association of all these biomarkers
and hyperandrogenemia together with obesity and IR,
determined IR by OGTT, and restricted the participants to
only adolescent girls. We found AMH and FAI but not BMI
as contributors to IR defined by OGTT, and we offered a
cutoff value for FAI to be used as an IR marker in PCOS.
In our study, the frequency of IR was found to be high
in both overweight/obese and nonobese girls with PCOS.
In the PCOS-NO group, the rate of IR detection by OGTT
was significantly higher than by HOMA-IR. Similarly,
Flannery et al. [34] proposed that glucose/insulin
metabolism should be evaluated in detail in patients with
PCOS independently of BMI, and that nonobese patients
with PCOS should be investigated in terms of impaired
glucose tolerance and IR. Coles et al. [35] reported that
OGTT was a superior diagnostic tool in assessing glucose
metabolism disorder. In light of our study’s results and
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current publications, it is clear that patients with PCOS
should be evaluated for IR in detail.
Our study showed a similar frequency of impaired
glucose tolerance in the PCOS-OW/O and PCOS-NO
groups. There were no patients with PCOS who met
the criteria for metabolic syndrome; however, a study
conducted by Hart et al. [36] reported that the risk of
developing metabolic syndrome was high in adolescents
with PCOS. Therefore, physicians should be alert in this
respect during patient follow-up visits.
In a metaanalysis that investigated the relationship
between IR and androgen levels in patients with PCOS,
it was found that SHBG had a strong association with
IR that was not confounded by BMI, and total T had a
moderate effect on IR [19]. Flannery et al. [34] showed
that nonobese patients with PCOS with impaired glucose
tolerance had similar T levels to those of obese patients.
In a study conducted by Reyes-Munoz et al. [37], which
sampled a large number of patients, it was reported that
total T levels were not different between overweight/obese
patients and normal weight patients with PCOS, whereas
significant differences in SHBG and FAI were observed.
We found a negative association between SHBG and IR in
our study, but when controlled for BMI, this association
disappeared. There was no relationship between total T
levels and obesity/IR parameters. However, consistent
with the literature, FAI was found to be more valuable
than using T or SHBG alone for monitoring IR in PCOS,
as it stayed as an effective factor on IR together with
AMH in regression analysis. Also FAI might be used as a
supporting IR marker at the cutoff value of 5.93, according
to ROC analysis.
INH-A was not found to be related to IR in a study
conducted by Segal et al. [9]; however, IR was evaluated
only by fasting insulin level in this study. For INH-B, some
studies have shown a negative association between INH-B
and insulin levels [22,23]. We found a negative correlation
between INH-A and HOMA-IR, even when controlled for
BMI. INH-B also had a negative correlation with HOMAIR, but the correlation disappeared when controlled for
BMI. However neither INH-A nor INH-B contribute to
IR (defined by OGTT) in regression analysis. According
to our results, INH-B is related to BMI, but more research
is needed to clarify the relationship of INH-A and INH-B
with IR in PCOS.
Studies conducted with PCOS patients emphasize that
there is an inverse correlation between BMI and AMH
[38–41]. However, these studies have been conducted with
adults. In a study conducted with adolescent girls with
PCOS, no difference was reported in AMH levels between
the groups with normal weight and the overweight/obese
patients [18]. Similarly, we found no relation between
AMH levels and BMI.
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Examination of the association between obesity/
IR parameters and AMH levels will provide a clearer
interpretation of the pathophysiology of PCOS. It has
been shown that AMH triggers hyperandrogenism and IR
in patients with PCOS [42]. There are some contradictory
results on the relationship between AMH and IR in
patients with PCOS. Skalba et al. [40] found a positive
correlation, while Feldman et al. [41] found a negative
correlation between AMH and IR. However, in the study
conducted by Skalba et al. [40], PCOS group consisted
only of patients with normal and overweight BMIs,
whereas Feldman et al. [41] also included obese patients
with PCOS. In two studies with a high number of PCOS
patients conducted by Cui et al. [38, 39] , AMH was found
to be not related to glucose/insulin metabolism and IR.
However, in these studies, the relationship between IR and
AMH were examined by HOMA-IR. In our study, IR was
evaluated by both HOMA-IR and OGTT. AMH did not
have a significant effect on IR in a regression model when
studied alone, but did when combined with FAI when
BMI was excluded from the equation. We urge that the
relationship between AMH and IR be investigated with

studies on a larger number of patients using OGTT or the
clamp test.
The present study presenting the preliminary results of
our ongoing work was conducted with a relatively limited
number of patients. Another limitation was the absence
of a control group due to the fact that no ethical approval
could be obtained for performing OGTT in a control
group.
In conclusion, OGTT is more reliable than HOMA-IR
in specifying IR in nonobese adolescent girls with PCOS.
Inhibin B is associated with BMI rather than IR. INH-A
is associated with HOMA-IR and this association is BMIindependent. Similarly, AMH and FAI together may
contribute to IR defined by OGTT and this contribution
is also BMI-independent. FAI can be used as a supporting
IR marker in PCOS.
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